Unknown

Dataset Information

0

Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK-648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction.


ABSTRACT: TAK-648 is a PDE4 inhibitor with demonstrated preclinical antidiabetic properties. Our objective was to develop a translational pharmacokinetic/pharmacodynamic (PK/PD) model for human type 2 diabetes (T2D) dose prediction using HbA1c results from a db/db mouse study. Estimated parameters in combination with tPDE4i values calculated for the clinical roflumilast dose of 500 ?g were used to translate preclinical effects of TAK-648 to required exposure in humans. A first-in-human study with single TAK-648 doses of 0.05-0.85 mg in healthy volunteers yielded mean maximum TAK-648 concentrations (Cmax) and area under the curve (AUC) values from 0.62-11.9 ?g/L and 4.58-93.8 ?g*h/L, respectively. Based on the performed pharmacokinetic/pharmacodynamic analysis and clinical PK results, clinical efficacy would be expected at a daily dose of 0.1 mg, which is well within the investigated clinical dose range. This result significantly enhanced the confidence in TAK-648 for type 2 diabetes treatment and underlines the necessity of translational approaches in early preclinical phases.

SUBMITTER: Plock N 

PROVIDER: S-EPMC5421726 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK-648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction.

Plock N N   Vollert S S   Mayer M M   Hanauer G G   Lahu G G  

Clinical and translational science 20170115 3


TAK-648 is a PDE4 inhibitor with demonstrated preclinical antidiabetic properties. Our objective was to develop a translational pharmacokinetic/pharmacodynamic (PK/PD) model for human type 2 diabetes (T2D) dose prediction using HbA<sub>1c</sub> results from a db/db mouse study. Estimated parameters in combination with tPDE4i values calculated for the clinical roflumilast dose of 500 μg were used to translate preclinical effects of TAK-648 to required exposure in humans. A first-in-human study wi  ...[more]

Similar Datasets

| S-EPMC8129711 | biostudies-literature
| S-EPMC11315854 | biostudies-literature
| S-EPMC10746753 | biostudies-literature
| S-EPMC5270293 | biostudies-literature
| S-EPMC6538812 | biostudies-literature
| S-EPMC10134386 | biostudies-literature
| S-EPMC4513223 | biostudies-literature
| S-EPMC8932701 | biostudies-literature
| S-EPMC4834132 | biostudies-literature
| S-EPMC3675733 | biostudies-literature